Omalizumab effectively prevents recurrent refractory anaphylaxis in a patient with monoclonal mast cell activation syndrome (original) (raw)

“…Several case reports combining omalizumab with venomspecific immunotherapy to improve the safety of the latter in mastocytosis patients have been published [127][128][129]. Omalizumab has been reported to be safe and effective in preventing recurrent anaphylaxis in several small case series [130][131][132][133][134][135]. The patients showed rapid and long-term efficiency of this treatment to control life-threatening mastocytosis-related symptoms.…”

Section: Anaphylaxismentioning

“…Additional study is required to determine the mechanism underlying this clinical observation. This is the third reported case of omalizumab use in MMAS and suggests that omalizumab may be an effective adjunct to therapy in patients with MMAS and life-threatening reactions refractory to maximal medical therapy [52].…”

Section: Various Treatmentsmentioning

“…Omalizumab was demonstrated to effectively prevent recurrent refractory anaphylaxis in a patient with monoclonal mast cell activation syndrome [52]. The authors present a case of MMAS with recurrent unprovoked life-threatening anaphylaxis responding to treatment with omalizumab.…”

Section: Various Treatmentsmentioning

See 2 more Smart Citations